# Barer & Son Capital

> Barer & Son Capital is a VC fund backing Biotechnology and Health Diagnostics. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Mendham, United States
- Total investments: 3
- Last investment: Jun 2020
- Lead investor: 33%
- Last updated: Aug 2026

Barer & Son Capital is a venture capital firm that seeks to invest in the healthcare and life science sector. The firm was founded in 2017 and is based in Mendham, New Jersey.

## Contacts

5 contacts available for Barer & Son Capital. Shizune tracks 1 team members at Barer & Son Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/barer-son-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Health Diagnostics | 2 | 67% |
| Medical | 1 | 33% |
| Wellness | 1 | 33% |
| Biopharma | 1 | 33% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |
| Convertible Note | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Joshua Barer | Managing Partner | 2 | https://shizune.co/investors/profile/joshua-barer |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AsclepiX Therapeutics | AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to designlong-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body.AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases. | $35M | Series A | Jun 24, 2020 |  |
| Viela Bio | Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases. The Company’s portfolio selectively targets shared critical pathways that are the root cause of disease. Led by a team of global leaders in inflammation and autoimmunity, Viela Bio strives to be a fully integratedbiotechnology company, helping millions of patients worldwide. Viela Bio is located in Gaithersburg, Maryland. | $75M | Series B | Jun 18, 2019 |  |
| AsclepiX Therapeutics | AsclepiX Therapeutics represents the next generation of biologics and drug development technology. They use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular), and anti-lymphangiogenic peptides. They also use the latest developments in biomaterials and drug delivery to designlong-lasting biodegradable nano and microparticles to deliver these biomimetic therapeutic peptides throughout the body.AsclepiX Therapeutics utilizes its platform technology for indications in ophthalmology, oncology, and for other angiogenesis and lymphangiogenesis-dependent diseases. | $5M | Convertible Note | Nov 13, 2018 |  |

3 of 3 investments shown.

## Co-investors
- [Rapha Capital Management](https://shizune.co/investors/profile/rapha-capital-management) — VC Fund, 2 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 1 deal together
- [Goldman Sachs](https://shizune.co/investors/profile/goldman-sachs) — VC Fund, 1 deal together
- [HBM Healthcare Investments](https://shizune.co/investors/profile/hbm-healthcare-investments-ag) — VC Fund, 1 deal together
- [TEDCO](https://shizune.co/investors/profile/maryland-technology-development-corporation) — VC Fund, 1 deal together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Barer & Son Capital invest in?

Barer & Son Capital invests primarily in Biotechnology, Health Diagnostics and Medical startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Barer & Son Capital?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Barer & Son Capital?

The team at Barer & Son Capital includes Joshua Barer (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co